Who is sponsoring NCT05594394?

NCT05594394 is sponsored by Methodist Health System.

What drugs are being tested in NCT05594394?

Interventions in NCT05594394: Orai: Master Public Speaking.

What condition does NCT05594394 study?

NCT05594394 studies Conflict Resolution.

Is NCT05594394 still recruiting?

NCT05594394 is currently completed. Last updated 24 March 2026.

Last reviewed 2026-03-24 · How we verify

NCT05594394

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Charge Nurse Conflict Resolution Communication Using Artificial Intelligence

Completed Last updated 24 March 2026

What this trial tests

trial testing Orai: Master Public Speaking in Conflict Resolution in 35 participants. Completed in 29 August 2023.

Timeline

19 September 2022

Primary endpoint
29 August 2023

29 August 2023

Quick facts

Lead sponsor	Methodist Health System
Status	Completed
Study type	OBSERVATIONAL
Enrollment	35
Start date	19 September 2022
Primary completion	29 August 2023
Estimated completion	29 August 2023
Sites	1 location across United States

Drugs / interventions tested

Orai: Master Public Speaking

Conditions studied

Conflict Resolution — all drugs for Conflict Resolution →

Sponsor

Methodist Health System — full company profile →

Who can join

Adults 18 to 75, any sex, with Conflict Resolution. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nurses are being challenged to provide increasingly complex care with more inexperienced nurses due to higher rates of retirement and registered nurse (RN) turnover in general. High-performing charge nurses with excellent interpersonal, conflict management, communication, and leadership competencies are vital to achieving optimal outcomes. Implementing a charge nurse leadership development program focused on improving communication competencies in conflict management situations can support a healthy work environment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Methodist Health System trials

Trials by the same sponsor.

NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
NCT07492758 — Management of Extremity Injuries Registry · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05594394 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
Last refreshed: 24 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05594394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing